Related Experiment Video

Updated: Jul 2, 2026

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

[Picrotoxin in the treatment of Menière's disease]

S Weikert1, A Rotter, H Scherer

  • 1Hals-Nasen-Ohrenklinik und Poliklinik Universitätsmedizin Berlin, Charité, Campus Mitte, Berlin. sebastian.weikert@charite.de

Laryngo- Rhino- Otologie
|August 23, 2008
PubMed
Abstract

Insights

Picrotoxin suppositories demonstrate superior effectiveness compared to betahistine for Meniere's disease treatment, significantly reducing vertigo attack frequency and intensity with no reported side effects.

Area of Science:

  • Neurology
  • Otolaryngology
  • Pharmacology

Background:

  • Meniere's disease management often involves long-term treatment strategies.
  • Picrotoxin suppositories are an uncommon prophylaxis despite empirical clinical benefit and a lack of side effects.
  • Limited clinical studies exist on the therapeutic effects of picrotoxin.

Purpose of the Study:

  • To evaluate the effectiveness of picrotoxin compared to betahistine in the long-term medical treatment of Meniere's disease.
  • To assess the impact of picrotoxin on vertigo attack frequency and intensity.

Main Methods:

  • A prospective clinical trial involving 41 patients with Meniere's disease.
  • Patients were treated with either betahistine (3x12 mg) or picrotoxin suppositories (0.001 g three times a week).
  • Vertigo attack frequency and intensity were evaluated before and during treatment over a mean follow-up period of 12 months.

Main Results:

  • Both treatment groups showed a statistically significant reduction in vertigo attack frequency and intensity.
  • Picrotoxin demonstrated significantly greater effectiveness in reducing both the frequency and intensity of vertigo attacks compared to betahistine.
  • The study reviewed the current state of medical long-term treatment for Meniere's disease in light of these findings.

Conclusions:

  • Picrotoxin is a viable alternative for the long-term medical management of Meniere's disease due to its clinical benefits and favorable side effect profile.
  • Picrotoxin warrants a significant role in the established treatment cascade for Meniere's disease.
  • Further research may explore picrotoxin's mechanisms and broader applications in otolaryngology.

More Related Videos

In Vivo Morphometric Analysis of Human Cranial Nerves Using Magnetic Resonance Imaging in Menière's Disease Ears and Normal Hearing Ears10:27

In Vivo Morphometric Analysis of Human Cranial Nerves Using Magnetic Resonance Imaging in Menière's Disease Ears and Normal Hearing Ears

Published on: February 21, 2018

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...